Sun Pharma gets approval for Winlevi in Australia
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Winlevi
Sun Pharma Canada launches WINLEVI for acne
WINLEVI is the first and only topical androgen receptor inhibitor
Cosmo, Glenmark signs distribution and license pacts for Winlevi in Europe, South Africa
Cassiopea will receive an upfront payment of $5 million, in addition to double-digit regulatory and sales milestones as well as…
Sun Pharma and Cosmo announce territory expansion of license and supply agreements for WINLEVI
The new agreement includes Japan, Australia, New Zealand, Brazil, Mexico and Russia
Sun Pharma launches acnce treatment cream in US
Winlevi is the first FDA-approved acne drug with a first-in-class mechanism of action in nearly 40 years, Sun Pharma said in a…
Sun Pharma and Cassiopea announce expiry of HSR Act process and consummation of Winlevi agreement
Sun Pharma now has the exclusive right to commercialse Winlevi in the United States and Canada. Cassiopea will be the exclusive…
Sun Pharma and Cassiopea SpA sign license and supply agreements for Winlevi
Winlevi is expected to be available in the US in Q4 calendar 2021
US FDA approves Winlevi, topical acne treatment from Cassiopea
Reportedly, the last FDA approval of an acne drug with a new mechanism of action (MOA) occurred nearly 40 years ago